ChemSpider 2D Image | sotagliflozin | C21H25ClO5S

sotagliflozin

  • Molecular FormulaC21H25ClO5S
  • Average mass424.938 Da
  • Monoisotopic mass424.111115 Da
  • ChemSpider ID27289071
  • defined stereocentres - 5 of 5 defined stereocentres


More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(5S)-5-[4-Chloro-3-(4-éthoxybenzyl)phényl]-1-thio-β-L-xylopyranoside de méthyle [French] [ACD/IUPAC Name]
1018899-04-1 [RN]
9824
LP-802034
LX 4211
LX4211
LX-4211
Methyl (5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-thio-β-L-xylopyranoside [ACD/IUPAC Name]
Methyl-(5S)-5-[4-chlor-3-(4-ethoxybenzyl)phenyl]-1-thio-β-L-xylopyranosid [German] [ACD/IUPAC Name]
sotagliflozin [INN] [USAN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

6B4ZBS263Y [DBID]
UNII:6B4ZBS263Y [DBID]
UNII-6B4ZBS263Y [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Bio Activity:

      LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. MedChem Express
      LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.; IC50 value:; Target: SGLT1/2; LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. MedChem Express HY-15516
      LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.;IC50 value:;Target: SGLT1/2LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glucose alone [2] MedChem Express HY-15516
      Membrane Tranporter/Ion Channel MedChem Express HY-15516
      Membrane Tranporter/Ion Channel; MedChem Express HY-15516
      SGLT MedChem Express HY-15516

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

Density: 1.4±0.1 g/cm3
Boiling Point: 607.9±55.0 °C at 760 mmHg
Vapour Pressure: 0.0±1.8 mmHg at 25°C
Enthalpy of Vaporization: 95.0±3.0 kJ/mol
Flash Point: 321.4±31.5 °C
Index of Refraction: 1.642
Molar Refractivity: 111.9±0.4 cm3
#H bond acceptors: 5
#H bond donors: 3
#Freely Rotating Bonds: 6
#Rule of 5 Violations: 1
ACD/LogP: 5.63
ACD/LogD (pH 5.5): 4.27
ACD/BCF (pH 5.5): 1036.45
ACD/KOC (pH 5.5): 5013.38
ACD/LogD (pH 7.4): 4.27
ACD/BCF (pH 7.4): 1036.44
ACD/KOC (pH 7.4): 5013.33
Polar Surface Area: 104 Å2
Polarizability: 44.4±0.5 10-24cm3
Surface Tension: 64.0±5.0 dyne/cm
Molar Volume: 309.7±5.0 cm3

Click to predict properties on the Chemicalize site






Advertisement